S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities

Bio-Techne (TECH) Competitors

$64.01
-1.51 (-2.30%)
(As of 04/16/2024 ET)

TECH vs. RGEN, QGEN, NBIX, EXEL, PCVX, CRSP, KRYS, HALO, IMVT, and IBRX

Should you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Repligen (RGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Vaxcyte (PCVX), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), Halozyme Therapeutics (HALO), Immunovant (IMVT), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.

Bio-Techne vs.

Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking.

Repligen received 15 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 68.03% of users gave Repligen an outperform vote while only 62.30% of users gave Bio-Techne an outperform vote.

CompanyUnderperformOutperform
Bio-TechneOutperform Votes
385
62.30%
Underperform Votes
233
37.70%
RepligenOutperform Votes
400
68.03%
Underperform Votes
188
31.97%

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 4.1% of Bio-Techne shares are held by company insiders. Comparatively, 1.2% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bio-Techne presently has a consensus price target of $84.11, indicating a potential upside of 30.93%. Repligen has a consensus price target of $196.70, indicating a potential upside of 19.75%. Given Bio-Techne's higher possible upside, equities analysts clearly believe Bio-Techne is more favorable than Repligen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Techne
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78
Repligen
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$1.14B8.86$285.26M$1.3846.41
Repligen$638.76M14.33$41.58M$0.72227.68

Bio-Techne has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Bio-Techne has a net margin of 19.58% compared to Repligen's net margin of 6.51%. Bio-Techne's return on equity of 14.21% beat Repligen's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Techne19.58% 14.21% 10.36%
Repligen 6.51%5.00%3.78%

In the previous week, Repligen had 5 more articles in the media than Bio-Techne. MarketBeat recorded 11 mentions for Repligen and 6 mentions for Bio-Techne. Repligen's average media sentiment score of 0.95 beat Bio-Techne's score of 0.91 indicating that Repligen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Techne
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Repligen
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Bio-Techne beats Repligen on 10 of the 18 factors compared between the two stocks.

Get Bio-Techne News Delivered to You Automatically

Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TECH vs. The Competition

MetricBio-TechneBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$10.07B$2.57B$4.72B$7.48B
Dividend Yield0.48%2.27%5.47%3.96%
P/E Ratio46.4122.56199.6415.37
Price / Sales8.86312.192,529.6388.05
Price / Cash26.52136.7333.3328.19
Price / Book5.133.844.694.26
Net Income$285.26M-$46.39M$100.13M$210.80M
7 Day Performance-10.08%-6.25%-4.81%-5.03%
1 Month Performance-11.68%-5.70%-3.53%-2.59%
1 Year Performance-24.86%10.24%12.34%6.38%

Bio-Techne Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGEN
Repligen
4.0171 of 5 stars
$181.92
+4.5%
$196.70
+8.1%
-4.4%$9.72B$638.76M252.671,783News Coverage
QGEN
Qiagen
4.2027 of 5 stars
$41.97
+1.1%
$51.69
+23.2%
-17.3%$9.58B$1.97B27.745,967
NBIX
Neurocrine Biosciences
4.418 of 5 stars
$138.94
-0.4%
$138.46
-0.3%
+28.2%$13.83B$1.89B57.411,400News Coverage
EXEL
Exelixis
4.9888 of 5 stars
$23.72
+1.6%
$26.29
+10.8%
+16.6%$7.19B$1.83B37.061,310Short Interest ↓
PCVX
Vaxcyte
1.772 of 5 stars
$64.51
+0.7%
$78.50
+21.7%
+70.9%$6.99BN/A-15.62254
CRSP
CRISPR Therapeutics
2.4246 of 5 stars
$65.19
+1.7%
$74.75
+14.7%
+16.7%$5.23B$371.21M-33.26473
KRYS
Krystal Biotech
3.5762 of 5 stars
$179.77
-0.4%
$157.67
-12.3%
+96.5%$5.13B$50.70M2,247.41229Analyst Report
HALO
Halozyme Therapeutics
4.9864 of 5 stars
$40.13
+0.6%
$53.29
+32.8%
+8.6%$5.10B$829.25M19.02373Analyst Report
IMVT
Immunovant
2.4591 of 5 stars
$31.17
+2.1%
$48.00
+54.0%
+113.5%$4.53BN/A-16.94164
IBRX
ImmunityBio
0.1131 of 5 stars
$6.16
-0.2%
$5.00
-18.8%
+171.5%$4.17B$620,000.00-5.31628Gap Down

Related Companies and Tools

This page (NASDAQ:TECH) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners